/INZY
INZY Stock - Inozyme Pharma, Inc.
Healthcare|BiotechnologyNASDAQ
$4.00+0.25%
+$0.01 (+0.25%) • Jul 1
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.91
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).50
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.28
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+0.0%upside
Target: $4.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INZY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.96 – $4.04
TARGET (TP)$4.00
STOP LOSS$3.68
RISK/REWARD1:0.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.29
52W High$6.24
52W Low$0.72
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-1,294,000 | $-1,177,000 | $-1,052,000 | $-217,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-104,030,000 | $-75,645,000 | $-68,675,000 | $-56,646,000 | $-57,041,000 |
| Net Income | $-102,024,000 | $-71,169,000 | $-65,447,000 | $-56,413,000 | $-55,837,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.62 | $-1.37 | $-1.73 | $-2.39 | $-2.39 |
Company Overview
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
80%
Hold / Neutral
1
20%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish1 Neutral/Bearish
Price Targets
$14
Average Target
↑ 250.0% Upside
Now
$5
Low
$14
Average
$26
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 12th 2024 | Raymond James | Initiation | Outperform | $26 |
| September 12th 2024 | Stifel | Initiation | Buy | $16 |
| August 13th 2024 | Jefferies | Resumed | Buy | $17← $16 |
| May 30th 2024 | Wells Fargo | Initiation | Overweight | $14 |
| March 23rd 2023 | Jefferies | Upgrade | Buy | $6← $4.5 |
| May 26th 2022 | Jefferies | Initiation | Hold | $5 |
Earnings History & Surprises
INZYBeat Rate
55%
Last 20 quarters
Avg Surprise
-11.9%
EPS vs Estimate
Beats / Misses
11/8
1 met exactly
Latest EPS
$-0.44
Q3 2025
EPS Surprise History
Q4 23
+9.4%
$-0.29vs$-0.32
Q1 24
-12.9%
$-0.35vs$-0.31
Q2 24
-8.6%
$-0.38vs$-0.35
Q3 24
-18.9%
$-0.44vs$-0.37
Q4 24
+11.4%
$-0.39vs$-0.44
Q1 25
0.0%
$-0.42vs$-0.42
Q2 25
-2.3%
$-0.44vs$-0.43
Q3 25
-22.2%
$-0.44vs$-0.36
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 5, 2025 | $-0.36 | $-0.44 | -22.2% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.43 | $-0.44 | -2.3% | ✗ MISS |
Q1 2025 | Mar 10, 2025 | $-0.42 | $-0.42 | 0.0% | = MET |
Q4 2024 | Nov 5, 2024 | $-0.44 | $-0.39 | +11.4% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.37 | $-0.44 | -18.9% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.35 | $-0.38 | -8.6% | ✗ MISS |
Q1 2024 | Mar 12, 2024 | $-0.31 | $-0.35 | -12.9% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.32 | $-0.29 | +9.4% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.43 | $-0.35 | +18.6% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.44 | $-0.40 | +9.1% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-0.46 | $-0.42 | +8.7% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.43 | $-0.38 | +11.6% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.48 | $-0.38 | +20.8% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.81 | $-0.71 | +12.3% | ✓ BEAT |
Q1 2022 | Mar 15, 2022 | $-0.73 | $-0.79 | -8.2% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.61 | $-0.60 | +1.6% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.57 | $-0.53 | +7.0% | ✓ BEAT |
Q2 2021 | May 12, 2021 | $-0.54 | $-0.47 | +13.0% | ✓ BEAT |
Q1 2021 | Mar 25, 2021 | $-0.55 | $-1.01 | -83.6% | ✗ MISS |
Q4 2020 | Nov 12, 2020 | $-0.51 | $-1.55 | -203.9% | ✗ MISS |
Frequently Asked Questions about INZY
What is INZY's current stock price?
Inozyme Pharma, Inc. (INZY) is currently trading at $4.00 per share. The stock has moved +0.25% today.
What is the analyst price target for INZY?
The average analyst price target for INZY is $4.00, based on 1 analyst.
What sector is Inozyme Pharma, Inc. in?
Inozyme Pharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is INZY's market cap?
Inozyme Pharma, Inc. has a market capitalization of $0.26 billion, making it a small-cap company.
Does INZY pay dividends?
No, Inozyme Pharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCATB
Catabasis Pharmaceuticals, Inc.
$8.54
Mkt Cap: $0.2B
CRGX
CARGO Therapeutics, Inc. Common Stock
$4.47
Mkt Cap: $0.2B
LSBCF
LakeShore Biopharma Co., Ltd
$0.84
Mkt Cap: $0.0B
SCPH
scPharmaceuticals Inc.
$5.67
Mkt Cap: $0.3B
SLRN
Acelyrin, Inc.
$2.27
Mkt Cap: $0.2B
SPPI
Spectrum Pharmaceuticals, Inc.
$1.02
Mkt Cap: $0.2B
TCRT
Alaunos Therapeutics, Inc.
$3.56
Mkt Cap: $0.0B
THRD
Third Harmonic Bio, Inc.
$5.38
Mkt Cap: $0.2B
TSVT
2seventy bio, Inc.
$5.00
Mkt Cap: $0.3B
VACC
Vaccitech plc
$5.00
Mkt Cap: $0.2B
Explore stocks similar to INZY for comparison